UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has completed the second phase of the on-going R&D collaboration project with Johnson & Johnson Enterprise Innovation Inc (J&J) and has delivered its final report.
The Joint Research Committee met last Friday where the LIDDS team delivered their final report as part of the on-going collaboration between LIDDS and J&J. The collaboration between LIDDS and J&J was formed in 2021 with the aim to develop an oncology product based on the NanoZolid® technology for an undisclosed indication. All results have now been communicated to J&J. The latter party will now consider these results and make a formal decision on whether to continue the program further.
“We have enjoyed the collaboration with J&J” says Matthew Lindon, Chief Scientific Officer at LIDDS. “The program was extended vs. the original plan. Now we have reached as far as we can within the scope of the current agreement. It is now up to J&J to decide on a possible continuation. We anticipate that J&J will make a formal decision on this in the relative near-term future”, he continues.